Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie, in collaboration with Genmab, is conducting a Phase 3 clinical trial titled ‘A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)’. The study aims to assess the safety and efficacy of combining subcutaneous epcoritamab with intravenous rituximab and oral lenalidomide in treating adult participants with previously untreated follicular lymphoma, a common and incurable type of B-cell cancer.
The trial is testing a combination of drugs including epcoritamab, an investigational drug, with rituximab and lenalidomide (R2), as well as other chemoimmunotherapy options. The primary goal is to evaluate adverse events and changes in disease activity among participants.
This interventional study is designed with a randomized allocation and a parallel intervention model. It is open-label, meaning no masking is used, and its primary purpose is treatment. Participants are divided into different groups to receive various combinations of the drugs over a treatment duration of up to 120 weeks.
The study began on December 20, 2023, and is currently recruiting participants. The primary completion date is yet to be determined, but the last update was submitted on September 1, 2025. These dates are crucial for tracking the progress and availability of results from the trial.
The outcome of this study could significantly influence AbbVie’s market position, potentially boosting investor confidence and impacting stock performance positively if results are favorable. It also positions AbbVie competitively in the oncology sector, where advancements in treatment options are highly sought after.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.